These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 17263826)

  • 1. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
    Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
    Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.
    Wollenberg A; Sidhu MK; Odeyemi I; Dorsch B; Koehne-Volland R; Schaff M; Ehlken B; Berger K
    Br J Dermatol; 2008 Dec; 159(6):1322-30. PubMed ID: 18782316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden--with model applications for Denmark, Norway and Finland.
    Hjalte F; Asseburg C; Tennvall GR
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):474-80. PubMed ID: 19793150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
    Pitt M; Garside R; Stein K
    Br J Dermatol; 2006 Jun; 154(6):1137-46. PubMed ID: 16704646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.
    Poole CD; Chambers C; Sidhu MK; Currie CJ
    Br J Dermatol; 2009 Dec; 161(6):1335-40. PubMed ID: 19754867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis.
    Taneja C; Antaya RJ; Berger A; Marshall TS; Seifeldin R; Oster G
    J Drugs Dermatol; 2010 Apr; 9(4):372-6. PubMed ID: 20514795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids.
    Poole CD; Chambers C; Allsopp R; Currie CJ
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):674-8. PubMed ID: 20565562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C;
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with atopic dermatitis: impact of tacrolimus ointment.
    Kawashima M;
    Int J Dermatol; 2006 Jun; 45(6):731-6. PubMed ID: 16796638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.
    Ellis CN; Drake LA; Prendergast MM; Abramovits W; Boguniewicz M; Daniel CR; Lebwohl M; Paller AS; Stevens SR; Whitaker-Worth DL; Tong KB
    J Am Acad Dermatol; 2003 Apr; 48(4):553-63. PubMed ID: 12664019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
    Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis.
    Chapman MS; Schachner LA; Breneman D; Boguniewicz M; Gold MH; Shull T; Linowski GJ; Jaracz E;
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S177-85. PubMed ID: 16021173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective.
    Healy E; Bentley A; Fidler C; Chambers C
    Br J Dermatol; 2011 Feb; 164(2):387-95. PubMed ID: 21083544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis.
    Bieber T; Vick K; Fölster-Holst R; Belloni-Fortina A; Städtler G; Worm M; Arcangeli F
    Allergy; 2007 Feb; 62(2):184-9. PubMed ID: 17298428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.